Trendlyne Blog: , Latest on stock market and finance in India and the world.

13 Apr 2025

1699.00

-1.65%

Drug makers Glenmark, Sun Pharma, Zydus recall products in US

Business Line

Companies initiate Class-II recall, which happens when use of, or exposure to, a violative product may lead to temporary or medically reversible health consequences

Sun Pharmaceutical Industries Ltd. is trading above its 50 day SMA of 1688.9

Glenmark, Sun Pharma, Zydus Recall Products In US

NDTV Profit | 13 Apr 2025

Wockhardt Ltd.

12 Apr 2025

1815.70

-0.67%

US tariffs, if extended to Indian pharma industry, will be a challenge: Wockhardt's Huzaifa Khorakiwala

Business Line

Confident that its product, WCK-5222-ZENIC, which has given 97% success in phase-3 clinical trials, would save millions of lives annually

Wockhardt Ltd. has gained 116.23% in the last 1 Year

Aurobindo Pharma Ltd.

11 Apr 2025

Aurobindo Pharma's US Plant Gets 11 FDA Observations

NDTV Profit

The inspection took place from March 24 to April 10, 2025.

Geojit BNP Paribas decreased Buy price target of Aurobindo Pharma Ltd. to 1348.0 on 04 Jul, 2025.

Sun Pharmaceutical Industries Ltd.

11 Apr 2025

1699.00

-1.65%

Sun Pharma stock up 2.4% as roads cleared for launch of alopecia drug

Business Standard

According to market estimates, Leqselvi is projected to contribute $90 million to Sun Pharma's sales in FY26, and $125 million in FY27

Sun Pharmaceutical Industries Ltd. is trading below its 100 day SMA of 1700.0

Here's why Sun Pharma share price advanced 5% in trade on April 11; details

Business Standard | 11 Apr 2025

Laurus Labs Ltd.

11 Apr 2025

821.95

-0.62%

Laurus Labs surges 8%, stock records sharpest intraday gain since Jan 30

Business Standard

The pipeline is expected to be robust, and the company expects to do well in the human health and animal health CDMO divisions in Q4FY25E and in FY26E, according to analysts.

Laurus Labs Ltd. has gained 23.30% in the last 1 Month

Biocon Ltd.

11 Apr 2025

394.35

1.00%

Biocon shares jump 5.5% as USFDA clears biosimilar Cancer drug JOBEVNE

livemint

Biocon's share price rose 5.5% after USFDA approved JOBEVNE, a biosimilar cancer drug. This marks the company's seventh USFDA-approved biosimilar and enhances its oncology portfolio, increasing investor confidence and market optimism.

Biocon Ltd. is trading above all available SMAs

Biocon subsidiary gets USFDA nod for Everolimus tablets; share zooms 6%

Business Standard | 11 Apr 2025 1 more

Morepen Laboratories Ltd.

11 Apr 2025

63.25

0.36%

Morepen to hire 1,000 medical representatives to boost formulations biz

Business Standard

Morepen Laboratories on Friday said it will add more than 1,000 medical representatives over the next three years, with over 200 team members expected to join in FY26 alone. The company aims to strengthen its formulations business in the market through new hirings. "This expansion represents a pivotal moment in Morepen's journey as we sharpen our focus on the expanding domestic finished dosage market," Morepen Laboratories Chairman and MD Sushil Suri said in a statement. With significant increase in the sales force and enhanced reach to doctors, pharmacies, and patients, the drugmaker is setting the stage for getting a bigger pie in the Indian pharmaceutical market valued at Rs 2.38 lakh crore, yielding higher gross margins and better returns for stakeholders in the long run, he added. Currently, Morepen's formulation business stands around Rs 325 crore, and the company is targeting to touch Rs 1,000 crore in the next five years. This goal will be supported by an aggressive expans

Morepen Laboratories Ltd. is trading below its 30 day SMA of 63.4

Cipla Ltd.

11 Apr 2025

1471.40

-1.31%

Cipla gets USFDA nod to market generic version of cancer drug Abraxane

Business Standard

Drug major Cipla on Friday said it has received approval from the US health regulator to market a generic cancer treatment drug. The company has received the final approval from the US Food and Drug Administration (USFDA) for the Abbreviated New Drug Application (ANDA) submitted for paclitaxel protein-bound particles for injectable suspension (albumin-bound), 100 mg/vial, single-dose vial, Cipla said in a regulatory filing. Cipla's protein-bound paclitaxel is a generic therapeutic equivalent version of Bristol Myers Squibb's Abraxane for injectable suspension 100 mg/vial. Protein-bound paclitaxel is indicated for the treatment of metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer and metastatic adenocarcinoma of the pancreas. The product is expected to be launched in the first half of the current fiscal year in the US, the Mumbai-based drugmaker said. Shares of the company were trading 2.73 per cent up at Rs 1,454.90 apiece on the BSE.